BENEFIT
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 666 kidney-transplant recipients, belatacept improved 7-year patient and graft survival compared with ciclosporin.
N
666
Disegno
Phase 3 RCT, 7-year follow-up
Esito
Death or graft loss at 7 years
Rilevanza
2
RisultatoHR 0.57 (95% CI 0.35–0.95; p=0.02); mean eGFR ~70 vs ~45 mL/min.
Vincenti F, et al. N Engl J Med. 2016;374(4):333-343. 10.1056/NEJMoa1506027
Discussione e critica
A CNI-free alternative with better kidney function; post-transplant lymphoproliferative risk restricts it to EBV-seropositive recipients.